Expand IMRX Menu
IMRX MENU

IMRX Stock Posts


Unusual Option Volume

IMRX Immuneering - Class A5.40+0.30 (+5.9%)

Immuneering - Class A trades 6,463 contracts. The highest volume is in the 21-Aug-26 7.5 calls, which is 38.9% above the current price.
Unusual Option Volume

IMRX Immuneering - Class A4.39-1.38 (-23.9%)

Immuneering - Class A trades 2,828 contracts. The company has the following event: 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Jun 1, 2026. News: Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
Unusual Option Volume

IMRX Immuneering - Class A6.82+1.60 (+30.7%)

Immuneering - Class A trades 2,800 contracts. The company has the following event: 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Jun 1, 2026. News: Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Unusual Option Volume

IMRX Immuneering - Class A5.07-3.26 (-39.1%)

IMRX stock declines -22.4% in after hours trading. See the latest news.

After Hours Decliner

IMRX Immuneering - Class A8.33+1.61+24.0%

After Hours:6.46-1.87 (-22.5%)

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Globe NewswireWed, 7-Jan 4:00 PM

IMRX stock declines -25.7% in after hours trading. See the latest news.

After Hours Decliner

IMRX Immuneering - Class A8.33+1.61+24.0%

After Hours:6.19-2.14 (-25.7%)

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Globe NewswireWed, 7-Jan 4:00 PM

Market Data Delayed 15 Minutes